.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
UBS
Cipla
Boehringer Ingelheim
Queensland Health
Cantor Fitzgerald
Mallinckrodt
Moodys
Argus Health

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,551,528

« Back to Dashboard

Which drugs does patent 8,551,528 protect, and when does it expire?


Patent 8,551,528 protects AFREZZA and is included in one NDA.

This patent has twenty-one patent family members in fifteen countries.

Summary for Patent: 8,551,528

Title:Diketopiperazine microparticles with defined specific surface areas
Abstract: Disclosed herein are diketopiperazine microparticles having a specific surface area of less than about 67 m.sup.2/g. The diketopiperazine microparticle can be fumaryl diketopiperazine and can comprise a drug such as insulin.
Inventor(s): Grant; Marshall L. (Newtown, CT), Stowell; Grayson W. (Gaylordsville, CT), Menkin; Paul (Branford, CT)
Assignee: Mannkind Corporation (Valencia, CA)
Application Number:12/813,857
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mannkind
AFREZZA
insulin recombinant human
POWDER;INHALATION022472-001Jun 27, 2014RXYesNo► Subscribe► SubscribeY
Mannkind
AFREZZA
insulin recombinant human
POWDER;INHALATION022472-002Jun 27, 2014RXYesYes► Subscribe► SubscribeY
Mannkind
AFREZZA
insulin recombinant human
POWDER;INHALATION022472-003Apr 17, 2015RXYesNo► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,551,528

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,734,845Diketopiperazine microparticles with defined specific surface areas► Subscribe
9,630,930Diketopiperazine microparticles with defined specific surface areas► Subscribe
8,778,403Diketopiperazine microparticles with defined specific surface areas► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,551,528

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China102647979► Subscribe
China104721825► Subscribe
European Patent Office2440184► Subscribe
Israel216911► Subscribe
Japan2012530064► Subscribe
Japan5859433► Subscribe
Japan2016028067► Subscribe
Japan6115795► Subscribe
Malaysia157166► Subscribe
South Korea20140015119► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Cerilliant
Chubb
Citi
Healthtrust
AstraZeneca
Julphar
Fuji
Deloitte
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot